Xenon Pharmaceuticals
XENE
151 hedge funds and large institutions have $1.62B invested in Xenon Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 17 closing their positions.
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
44% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 39
14% more funds holding
Funds holding: 133 → 151 (+18)
13% more capital invested
Capital invested by funds: $1.44B → $1.62B (+$181M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
1.22% less ownership
Funds ownership: 94.71% → 93.49% (-1.2%)
74% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $4.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$49.6M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$33M |
| 3 |
Holocene Advisors
New York
|
+$27.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.3M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.7M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$21.2M |
| 3 |
Morgan Stanley
New York
|
-$13.4M |
| 4 |
Goldman Sachs
New York
|
-$12.9M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$9.32M |
XENE Hedge Fund Activity: Q2 2022 in Review
151 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2022, worth a combined $1.62B — up 13% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new XENE positions and 17 closed out — a net gain of 20 holders — while 56 added to existing stakes and 39 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $37.7M.
- 151 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2022, up from 133 in Q1 2022.
- Funds reported $1.62B of Xenon Pharmaceuticals stock for Q2 2022, up 13% quarter-over-quarter.
- 37 funds opened new Xenon Pharmaceuticals positions in Q2 2022 and 17 closed out, a net change of +20 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2022 was Redmile Group, an estimated $49.6M added.
- The largest Xenon Pharmaceuticals seller in Q2 2022 was Point72 Asset Management, an estimated $37.7M sold.
Based on aggregated 13F filings for Q2 2022.